2-Cyanophenylboronic Acidum 1,3-Propanediolum Ester CAS 172732-52-4 Perampanel Intermedia Puritas >99.0% (HPLC)
Shanghai Ruifu Chemical Co., Ltd. est primarius fabrica 2-cyanophenylboronicae acidi 1,3-Propanediolis Ester (CAS: 172732-52-4) cum qualitate media Perampanel (CAS: 380917-97-5).Ruifu Chemical traditio totius terrarum, quantitatis competitive pretium, optimum servitium, parvas et moles in promptu habere potest.Purchase Perampanel media, Please contact: alvin@ruifuchem.com
Nomen chemicum | 2-Cyanophenylboronic Acidum 1,3-Propanediolum Ester |
Synonyma | 2-Cyanobenzeneboronic Acidum 1,3-Propanediol Ester;2-(1,3,2-Dioxaborinan-2-yl) benzonitrile |
CAS Number | 172732-52-4 |
Stock Status | In Stock, Productio Ascendite ad Tons |
Formulae hypotheticae | C10H10BNO2 |
M. Pondus | 187.01 |
Liquescens punctum | 46.0~51.0℃ (lit.) |
Density | 1.13±0.10 g/cm3 |
Solubilitas | Solutum in Methanol |
Stabilitas | Hygroscopic |
Brand | Ruifu Chemical |
Item | Specifications |
Aspectus | Alba ad lux Yellow pulveris ad Crystal |
Puritas / Analysis Methodus | >99.0% (HPLC) |
Damnum in Siccatio | <0.50% |
Residere in Ignition | <0.20% |
una immunditia | <0.50% |
Totalis immunditias | <1.00% |
Metalla gravia (ut Pb) | <20ppm |
Test Standard | Enterprise Standard |
Consuetudinem | Medium Perampanel (CAS: 380917-97-5) |
sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris.
Repono Condition:Repone in vasis signatis in loco frigido et sicco;A luce et humore protege.
Periculosam symbola Xi - Irritant
Periculum Codes
R20/21/22 - Inspiratio noxia, in contactu cum cute et absorpta.
R36/37/38 - Irritando ad oculos, systema respiratorium et cutem.
Salus Descriptio
S26 - In contactu cum oculis, statim cum aqua multa ablue et consilium medicinae quaeras.
S36/37/39 - Indumentum tutelae idoneum, chirothecae et oculi / faciei tutelam indue.
UN IDs 3439
WGK Germania 3
TSCA No
Aleam Nota Irritant
2-Cyanophenylboronic Acidum 1,3-Propanediol Ester (CAS: 172732-52-4) in synthesi Perampanel (CAS: 380917-97-5), receptator AMPA adversariorum.Perampanel (licentiatus anno 2012) tertia generatio AED est nota proprietatis notae nomine Fycompa® (Eisai, Hatfield) in UK et Banzel® (Eisai, Hatfield) in USA.Mense Octobri MMXII, US FDA perampanel probatus est pro curatione captionis partialis incursus in aegros epilepticis qui sunt saltem 12 annos natus.Perampanel primus est AMPA receptor adversarius ad probandum FDA recipiendum ut AED.AMPA receptores glutamatos principaliter inveniuntur in neuronibus postsynapticis in cerebro.Sicut selectivum, noncompetitivum AMPA impugnator, parampanel impedit canalem ion aperiendi et propagationem potentiae actionis reducens.Perampanel ab Europaeis EMA et US FDA mense Iulio et Octobri 2012 anno 2012 probatus est, adhibita curatione aegrorum partialium invasiones per 12 annos nata cum aut sine captionibus systemicis secundariis.Die 22 Iunii 2015, Eisai nuntiavit US FDA dilatationem significationis hydratis Pirenparanidis (Fycompa) adiuvantem curationem ad primas captiones tonico-clonicas in patientibus epilepsiae aetatis 12 et supra patientibus approbasse.